BridgeBio Oncology Therapeutics Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number:001-41955 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)256 E. Grand Avenue,Suite 104South San Francisco,CA(Address of principal executive offices) Registrant’s telephone number, including area code: (650)405-4770 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of November 7, 2025, the registrant had79,988,687shares of common stock, $0.0001 par value per share, outstanding. Table ofContents Item 1.Financial StatementsUnaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September30, 2025 and 2024Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months endedSeptember 30, 2025 and 2024Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders'Equity (Deficit) for the periods ended September 30, 2025 and 2024Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025and 2024Notes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures 3838949494959698 PART I—FINANCIAL INFORMATION BridgeBio Oncology Therapeutics, Inc.Unaudited Condensed Consolidated Balance Sheets(In thousands, except shares and per share data) BridgeBio Oncology Therapeutics, Inc.Unaudited Condensed ConsolidatedStatements of Operations(In thousands, except shares and per share data) Research and development expenses include related party amounts of$153and$590for the three and nine months endedSeptember 30, 2025, respectively. Research and development expenses include related party amounts of$636and$8,645for thethree and nine months ended September 30, 2024, respectively.(1) General and administrative expenses include related party amounts of$7,905and$8,274for the three and nine months endedSeptember 30, 2025, respectively. General and administrative expenses include related party amounts of$226and$2,615for thethree and nine months ended September 30, 2024, respectively.(2) Noincome from related parties was recognized in connection to transition services agreements for thethree and nine monthsended September 30, 2025. Income from transaction services agreements includes related party amounts of$432and$716forthe three and nine months ended September 30, 2024, respectively.(3) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. BridgeBio Oncology Therapeutics, Inc.Unaudited Condensed Consolidated Statements of Redeemable Convertible PreferredStockand Stockholders’ Equity (Deficit)(In thousands, except